Figure 5.

Inhibition of NOS Reverses the Impaired Cardiac Post-Ischemic Recovery Induced by db/db RBCs

(A) Hearts from WT mice were given RBCs from db/db mice incubated with vehicle (n = 5), the arginase inhibitor nor-NOHA (1 mmol/l, n = 8) or the NOS inhibitor L-NAME (0.1 mmol/l) + nor-NOHA (1 mmol/l, n = 5). (B) Hearts from WT mice were given RBCs from db/db mice incubated with vehicle (n = 5), nor-NOHA (3 mmol/l, n = 4), or L-NAME (0.1 mmol/l) + nor-NOHA (3 mmol/l, n = 6). (C) Hearts from WT mice were given RBCs from db/db mice incubated with vehicle (n = 5) or L-NAME (0.1 mmol/l, n = 5). (D) Hearts from WT mice were given RBCs from WT mice incubated with vehicle (n = 6) or L-NAME (0.1 mmol/l, n = 5). Post-ischemic LVDP is expressed as percentage recovery from the pre-ischemic level. Significant differences between treatments were analyzed using 2-way analysis of variance including all time points; ***p < 0.001. Abbreviations as in Figures 1, 2, 3, and 4.